Table 1 Demographic and clinical variables of the pregnant participants included in the study. SARS-CoV-2-positive participants and SARS-CoV-2-negative (healthy controls) were recruited at the University of Massachusetts Memorial Hospital from April 27 to June 10, 2020. Additionally, SARS-CoV-2 negative (healthy controls) were recruited nationwide prior to the COVID-19 pandemic
From: The microbiota of pregnant women with SARS-CoV-2 and their infants
Demographics and clinical variables | SARS-CoV-2-positive pregnant women (N = 62) | Healthy controls pregnant women (N = 26) | Total (N = 88) | P valuea |
|---|---|---|---|---|
Age | Â | Â | Â | 0.032 |
 Mean (SD) | 31.0 (6.24) | 33.4 (4.96) | 31.7 (5.97) |  |
Body mass index | ||||
 Pre-pregnancy |  |  |  | 0.473 |
  Mean (SD) | 31.2 (6.93) | 29.5 (7.33) | 30.7 (7.05) |  |
 Pre-pregnancy category |  |  |  | 0.321 |
  Underweight | 1 (1.6%) | 1 (3.8%) | 2 (2.3%) |  |
  Normal | 11 (17.7%) | 4 (15.4%) | 15 (17.0%) |  |
  Overweight | 20 (32.3%) | 13 (50.0%) | 33 (37.5%) |  |
  Obese | 30 (48.4%) | 8 (30.8%) | 38 (43.2%) |  |
Race | Â | Â | Â | 0.048 |
 Non-Hispanic White | 29 (46.8%) | 18 (69.2%) | 47 (53.4%) |  |
 Hispanic or Latino | 24 (38.7%) | 2 (7.7%) | 26 (29.5%) |  |
 Non-Hispanic Black | 7 (11.3%) | 4 (15.4%) | 11 (12.5%) |  |
 Non-Hispanic Asian | 2 (3.2%) | 2 (7.7%) | 4 (4.5%) |  |
SARS-CoV-2 comorbidities | ||||
 Type 2 diabetes | 4 (6.5%) | 2 (7.7%) | 6 (6.8%) | 0.889 |
 Cardiovascular disease | 12 (19.4%) | 4 (15.4%) | 16 (18.2%) | 0.669 |
Pregnancy outcomes | ||||
 Vaginal delivery | 43 (69.4%) | 16 (61.5%) | 59 (67.0%) | 0.621 |
 Preeclampsia | 9 (14.5%) | 2 (7.7%) | 11 (12.5%) | 0.549 |
 Preterm (≤ 37 weeks) | 14 (22.6%) | 3 (11.5%) | 17 (19.3%) | 0.181 |
 Gestational diabetes | 13 (21.0%) | 3 (11.5%) | 16 (18.2%) | 0.502 |
 Antibiotic during delivery | 24 (38.7%) | 12 (46.2%) | 36 (40.9%) | 0.724 |
 Antibiotic before delivery | 5 (8.1%) | 0 (0%) | 5 (5.7%) | 0.341 |
 Vaccinated against SARS-CoV-2 | 1 (1.6%) | 9 (34.6%) | 10 (11.4%) | 3.00E − 05 |